跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
設備
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
蔡 明宏
臨床副教授
,
醫學系
電子郵件
D000013713
cgu.edu
tw
h-index
h10-index
h5-index
2883
引文
31
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1566
引文
22
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
338
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2025
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(5)
研究產出
(120)
獎項
(1)
相近領域學者
(6)
指紋
查看啟用 Ming-Horng Tsai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Neonates
100%
Child
75%
Patient
69%
Therapeutic Procedure
49%
Neonatal Intensive Care Unit
47%
Mortality
44%
Bloodstream Infection
38%
Odds Ratio
34%
Incidence
31%
Combination Therapy
30%
Sepsis
30%
Hospital
28%
Bacteremia
26%
Clinical Feature
25%
Infant
24%
Respiratory Failure
24%
Diagnosis
23%
Experience
22%
Ventilator-Associated Pneumonia
21%
Age
20%
Attention Deficit Disorder
19%
Streptococcus Agalactiae
18%
Prematurity
18%
Analysis
18%
Mortality Rate
17%
Antibiotics
17%
Disease
16%
Girl
16%
Cancer Cell
14%
Serotype
14%
Transplantation
14%
Reactive Oxygen Species
14%
Adverse Outcome
13%
Sleep
13%
Pediatrics
13%
Species
12%
Pathogen
12%
Antibiotic Therapy
12%
Septic Shock
12%
Meningitis
12%
Neurological Complication
12%
Infection
12%
Hospital Mortality
12%
Cord Blood
11%
Rescue Therapy
11%
Morbidity
10%
Infectious Complication
10%
Fatty Liver
10%
Gram Negative Sepsis
9%
Water
9%
Pharmacology, Toxicology and Pharmaceutical Science
Sepsis
29%
Prostaglandin E2
25%
Bloodstream Infection
21%
Ventilator Associated Pneumonia
20%
Respiratory Failure
19%
Apoptosis
19%
Bacteremia
19%
Incidence
19%
Reactive Oxygen Metabolite
18%
Mortality
18%
Cyclooxygenase 2
18%
Antibiotic Therapy
16%
Flavonoid
16%
Prematurity
15%
Streptococcus Agalactiae
15%
Antibiotics
14%
Diseases
14%
Antibiotic Agent
12%
Nanoparticle
12%
Inflammation
12%
Infectious Agent
11%
Mouse
10%
Candidemia
10%
Infectious Complication
9%
Protein
9%
Gram Negative Sepsis
9%
Protein P53
9%
Glioblastoma
9%
Non Small Cell Lung Cancer
9%
Chia
9%
Mortality Rate
9%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
9%
Antioxidant
8%
Interleukin 6
8%
Meningitis
7%
Water
7%
Gelatinase B
7%
Mitogen Activated Protein Kinase 3
7%
Morbidity
7%
Infection
6%
Antimicrobial Resistance
6%
Melanoma
6%
Candida
6%
Penicillinase
6%
Adverse Outcome
6%
Septic Shock
6%
Antiinfective Agent
6%
Nitric Oxide
5%
Malignant Neoplasm
5%
Staphylococcus Aureus
5%
Nursing and Health Professions
Sepsis
39%
Neonatal Intensive Care Unit
34%
Odds Ratio
28%
Confidence Interval
25%
Respiratory Failure
24%
Central Venous Catheter
19%
Bloodstream Infection
19%
Mortality
19%
Incidence
19%
Neonates
18%
Combination Therapy
15%
Catheter
15%
Very Low Birth Weight
14%
Analysis
13%
Clinical Feature
13%
Hospital Mortality
12%
Control
12%
Complication
12%
Ventilator-Associated Pneumonia
11%
Treatment Outcome
11%
Prematurity
10%
Nonalcoholic Fatty Liver
9%
Metabolic Syndrome X
9%
Candidemia
9%
Infant
9%
Alanine Aminotransferase
8%
Aspartate Aminotransferase
8%
Mortality Rate
8%
Prediction
8%
Infectious Complication
8%
Intubation
7%
Cohort Analysis
7%
Bacteremia
7%
Morbidity
7%
Adverse Outcome
7%
Virus Hepatitis
6%
Hospitalization
6%
Treatment Failure
6%
Antibiotic Agent
5%
Gestational Age
5%
Septic Shock
5%
Algorithm
5%
Fatty Liver
5%
Area under the Curve
5%
Data Base
5%
Catheter Infection
5%
Logistic Regression Analysis
5%
Case-Control Study
5%
Premature Infant
5%
